October 2015

Pharma major Biocon on Tuesday reported Rs.306 crore net profit for second quarter of 2015-16, a whopping 200 percent growth over the same period last year due to income from the public issue of its research arm Syngene International Ltd.

The Food Safety and Standards Authority of India (FSSAI) will come out with new regulations on product approvals in a few months, a senior government official said on Tuesday.

Mice studies by researchers at University of Toronto have revealed that nicotine gives brain more codeine relief, putting smokers at a higher risk for addiction. The study is published in Neuropsychopharmacology.

Pfizer Inc's subsidiary Hospira has secured an Indian patent for an improved process for the preparation of Cilastatin. Cilastatin is a chemical which acts with anti-biotic Imipenem for the treatment of infections in various body systems. Imipenem and Cilastatin are combined in a drug to make an anti-biotic.  It is used to treat serious infections that are mild to moderate in severity, such as lower respiratory infection and heart valve infection.

A team of researchers has revealed that regularly exercising before pregnancy protects against so-called pelvic girdle pain as the fetus grows. The study is published in the British Journal of Sports Medicine.

U.S. health regulators declined to approve a fixed-dose diabetes drug combination from AstraZeneca, delaying its launch and dealing a blow to an important plank of the drugmaker's business. Food and Drug Administration (FDA) stating that more clinical data were required before it could approve the combination of saxagliptin and dapagliflozin.